Core Insights - The search for profitable stocks in San Francisco revealed unexpected results, with a focus on biotech and other sectors rather than solely A.I. related companies [1][2] Company Performance - Nektar Therapeutics (NKTR) is the top performer, with a 150% increase in the past 90 days, focusing on treatments for dermatitis and Alopecia areata, with a bullish price target of $93.60 from analysts [5] - Sunrun (RUN), a solar power company, has doubled in value over three months, experiencing significant volatility, with shares fluctuating from $6 to above $20 [6] - The RealReal (REAL), a resale company for luxury items, is trading slightly above the median price target set by analysts, indicating potential caution for investors [7] - Planet Labs (PL), an 'earth intelligence' company, has seen its stock nearly double in a year, with sales more than doubling over the last four years, though it has experienced volatility [8] - Other notable companies include Fastly (FSLY), Maze Therapeutics (MAZE), Olema Pharmaceuticals (OLMA), Septerna (SEPN), and Cytokinetics (CYTK), all of which have performed well recently, particularly in the biotech sector [9]

Core Viewpoint - Citigroup raised Sunrun's target price from $11 to $26 and upgraded its rating from "Neutral" to "Buy" [1] Group 1 - The target price adjustment indicates a significant positive outlook for Sunrun's stock performance [1] - The upgrade in rating reflects increased confidence in Sunrun's business prospects and market position [1]

Core Viewpoint - The perception of a decline in the solar industry, particularly regarding Sunrun, is overstated, as evidenced by a significant stock price increase following a target price raise by RBC Capital [1] Company Performance - Sunrun's stock rose over 5% after RBC Capital increased its target price by 38% to $22, which is above its current share price [1] - Over the past 12 months, Sunrun's stock has appreciated by 40.31%, and its weighted alpha stands at 198.61, indicating potential for continued near-term gains [2] - Among 22 analysts covering Sunrun, 12 have rated it a Buy with an average rating of 4.05 out of 5, an increase from 3.70 three months ago [3] Financial Metrics - Sunrun is projected to earn $1 per share in 2025 and only $0.11 in 2026, resulting in a valuation of 20.5 times 2025 EPS and 186 times 2026 EPS, highlighting a significant valuation gap [6] - In Q2, Sunrun reported a 9% increase in revenues and a net income of $279.8 million, which is a 101% increase compared to the same quarter in 2024 [6][7]

Upgrades - BofA upgraded Eversource (ES) to Buy from Neutral with a price target of $85, up from $73, citing an "improving regulatory tone" and a projected 6% EPS growth through 2029 [2] - Leerink upgraded Exelixis (EXEL) to Outperform from Market Perform with a price target of $48, up from $38, following the Phase 3 STELLAR-303 trial results, which established important levers for long-term investment despite a 12% stock decline [3] - Citi upgraded Nextracker (NXT) to Buy from Neutral with a price target of $114, up from $66, highlighting its dominant position in tracker sales and potential revenue contributions from acquired businesses by FY30 [4] - Citi upgraded Sunrun (RUN) to Buy from Neutral with a price target of $26, up from $11, noting benefits from rising electricity rates and increased leverage over suppliers due to market shifts [5] - Raymond James upgraded Capri Holdings (CPRI) to Outperform from Market Perform with a price target of $25, indicating a favorable turnaround position supported by improving demand and conservative guidance [6] Downgrades - JPMorgan downgraded Goldman Sachs (GS) to Neutral from Overweight with a price target of $750, up from $625, citing high current valuations compared to European investment banks [7] - BNP Paribas Exane downgraded Verizon (VZ) to Neutral from Outperform with a price target of $44, raising concerns about strategic direction following a recent CEO change [7] - BNP Paribas Exane downgraded NuScale Power (SMR) to Underperform from Neutral with a price target of $25, down from $41, due to concerns over cumulative shipments and financial commitments [7] - Citi downgraded NuScale to Sell from Neutral with a price target of $37.50, down from $46, highlighting potential sales by Fluor and stretched valuations [7] - TD Cowen downgraded Tempus AI (TEM) to Hold from Buy with a price target of $88, up from $72, viewing the stock as fairly valued after a significant rally [7] - Wells Fargo downgraded Cleveland-Cliffs (CLF) to Underweight from Equal Weight with an unchanged price target of $11, describing the recent stock rally as "excess exuberance" [7]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - AlphaVest Acquisition Corp (ATMV) is up 71% at $14.24 [3] - BranchOut Food Inc. (BOF) is up 44% at $3.04 [3] - rYojbaba Co., Ltd. (RYOJ) is up 35% at $5.14 [3] - GSI Technology, Inc. (GSIT) is up 25% at $16.24 [3] - Jowell Global Ltd. (JWEL) is up 18% at $2.02 [3] - General Motors Company (GM) is up 9% at $63.68 [3] - Crown Holdings, Inc. (CCK) is up 8% at $103.00 [3] - Spero Therapeutics, Inc. (SPRO) is up 8% at $2.49 [3] - Sunrun Inc. (RUN) is up 6% at $21.90 [3] - Foxx Development Holdings Inc. (FOXX) is up 5% at $4.50 [3] Premarket Losers - Neuphoria Therapeutics Inc. (NEUP) is down 66% at $5.19 [4] - New Era Energy & Digital, Inc. (NUAI) is down 9% at $5.09 [4] - Odyssey Marine Exploration, Inc. (OMEX) is down 8% at $3.28 [4] - Carbon Revolution Public Limited Company (CREV) is down 7% at $4.86 [4] - Coeur Mining, Inc. (CDE) is down 7% at $20.38 [4] - Hecla Mining Company (HL) is down 6% at $13.50 [4] - Verrica Pharmaceuticals Inc. (VRCA) is down 6% at $4.12 [4] - Sensei Biotherapeutics, Inc. (SNSE) is down 5% at $10.06 [4] - Whitehawk Therapeutics, Inc. (WHWK) is down 5% at $2.52 [4] - Greenidge Generation Holdings Inc. (GREE) is down 5% at $2.07 [4]

Group 1 - Mr. Mavroudis is a professional portfolio manager with a focus on risk management and in-depth financial market analysis [1] - He has successfully navigated major crises, including the COVID-19 pandemic and the PSI [1] - Mr. Mavroudis is the CEO of FAST FINANCE Investment Services, a registered Greek company [1] Group 2 - He holds multiple degrees, including an MSc in Financial and Banking Management, an LLM in Law, and a BSc in Economics [1] - Mr. Mavroudis is certified in various financial disciplines, including portfolio management and derivatives [1] - He engages with the investment community through writing on Seeking Alpha and aims to foster mutual growth and knowledge sharing [1]

Group 1 - Mr. Mavroudis is a professional portfolio manager with a focus on risk management and in-depth financial market analysis [1] - He has successfully navigated major crises, including the COVID-19 pandemic and the PSI [1] - Mr. Mavroudis is the CEO of FAST FINANCE Investment Services, a registered Greek company [1] Group 2 - He holds multiple degrees, including an MSc in Financial and Banking Management, an LLM in Law, and a BSc in Economics [1] - Mr. Mavroudis is certified in various financial disciplines, including portfolio management and derivatives [1] - He engages with the investment community through writing and teaching, aiming for mutual growth and knowledge sharing [1]

Core Viewpoint - BMO analysts upgraded the stock rating to Market Perform from Underperform and increased the price target to $19 from $10 [1] Summary by Category - **Stock Rating Change** - The stock rating was upgraded to Market Perform from Underperform [1] - **Price Target Adjustment** - The price target was raised to $19 from $10, indicating a significant increase in expected value [1]

Group 1 - Sunrun Inc's shares increased by 3.9% to $21.49, reaching a two-year high of $22.44, following an upgrade from BMO Capital [1] - BMO Capital upgraded Sunrun from "underperform" to "market perform" and raised its price target from $10 to $19, citing an improved cash position and potential for buybacks and shareholder returns [1] - The stock has shown strong performance, gaining 134.4% in 2025, supported by an ascending 30-day moving average [2] Group 2 - There is potential for further bullish sentiment, as nine brokerages currently have a "hold" or worse recommendation on Sunrun, indicating room for price target increases [2] - The average 12-month price target for Sunrun is $16.76, which is 22.4% lower than the recent closing price, suggesting potential for upward adjustments [2] - Options for Sunrun appear attractive, with a Schaeffer's Volatility Index (SVI) of 111%, indicating low volatility expectations compared to historical readings [3]

Core Points - Sunrun will release its third quarter 2025 earnings report on November 6, 2025, after market close [1] - A conference call to discuss the earnings results is scheduled for 1:30 p.m. Pacific Time on the same day [2] - Sunrun is the largest provider of residential battery storage and solar power in the U.S., offering a no-upfront-cost subscription model [3] Company Overview - Sunrun Inc. is a pioneer in home energy systems, providing customers with energy control, security, and independence [3] - The company supports the grid by offering dispatchable power, which helps prevent blackouts and reduce energy costs [3] Investor Relations - Contact information for investor relations is provided, including Patrick Jobin as the SVP, Deputy CFO & Investor Relations Officer [4]